127P Does radiomics have added value in predicting the development of brain metastases in patients with radically treated stage III non-small cell lung cancer (NSCLC)?

L. Hendriks,S.A. Keek,A. Chatterjee,J. Belderbos,G. Bootsma,B. van den Borne,A-M.C. Dingemans, H. Gietema,H.J.M. Groen, G. Herder, C. Pitz, J. Praag,D. De Ruysscher, J. Schoenmaekers, H.J.M. Smit, J. Stigt, M. Westenend,H. Zeng,H. Woodruff,P. Lambin

ANNALS OF ONCOLOGY（2022）

引用 1|浏览16

暂无评分

摘要

Despite radical intent therapy for patients (pts) with stage III NSCLC, cumulative incidence of brain metastasis (BM) reaches 30%. Current risk stratification fails to identify these pts. Radiomics features (fts) from chest CTs have shown to have predictive value. We aimed to develop a model combining existing clinical risk factors with radiomics fts for BM development in stage III NSCLC.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要